GIPERTENZIYA, DISLIPIDEMIYA, SEMIZLIK VA METABOLIK SINDROMNI BOSHQARISH: KARDIOVASKULYAR PROFILAKTIKANING DALILLARGA ASOSLANGAN YONDASHUVI.

Authors

  • Mamajonova Muslima Umidjon qizi Respublika shoshilinch tibbiy yordam ilmiy markazi, kardiolog Author

Keywords:

arterial gipertenziya, dislipidemiya, semizlik, metabolik sindrom, LDL-xolesterin, yurak-qon tomir xavfi, ateroskleroz, kardiometabolik profilaktika.

Abstract

Arterial gipertenziya, dislipidemiya, semizlik va metabolik sindromni boshqarish yurak-qon tomir kasalliklarining oldini olishda muhim ahamiyatga ega. Bu yondashuv laboratoriya ko‘rsatkichlarini me’yorlashtirish bilangina cheklanmaydi. Uning asosiy maqsadi aterosklerotik yurak-qon tomir kasalligi, yurak yetishmovchiligi, buyrak kasalligi va 2-tip diabet xavfini uzoq muddat davomida kamaytirishdir. Ushbu maqolada mazkur xavf omillarining epidemiologik va patofiziologik o‘zaro bog‘liqligi, ularni aniqlash mezonlari hamda turmush tarzini o‘zgartirish va farmakologik davolashning dalillarga asoslangan tamoyillari tahlil qilindi. Tahlil 2024-yilgi ESC arterial gipertenziya qo‘llanmasi, ESC/EAS dislipidemiya tavsiyalari, WHO ma’lumotlari, AHA/NHLBI metabolik sindrom mezonlari va randomizatsiyalangan klinik tadqiqotlar natijalariga tayandi. Mavjud dalillar sistolik qon bosimini barqaror pasaytirish, LDL-xolesterinni xavf darajasiga mos kamaytirish, tana vazni va visseral yog‘lanishni nazorat qilish hamda metabolik sindrom komponentlarini birgalikda davolash yurak-qon tomir hodisalarini kamaytirishini ko‘rsatadi. Shuning uchun bemorni boshqarish “bitta omil — bitta dori” modeliga emas, balki mutlaq xavf, klinik foyda, davolashga rioya qilish va bemorning afzalliklarini hisobga oladigan integratsiyalashgan yondashuvga qurilishi kerak

Downloads

Download data is not yet available.

References

1. World Health Organization. Obesity and overweight: fact sheet. 2025.

2. World Health Organization. Noncommunicable diseases: fact sheet. 2025.

3. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. Circulation. 2009. 120:1640–1645.

4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021. 397:1625–1636.

5. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024.

6. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet. 2010. 376:1670–1681.

7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin. Lancet. 2002. 360:7–22.

8. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020. 41:111–188.

9. World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Geneva: WHO. 2020.

Downloads

Published

2026-10-05